Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farabi Pharmaceutical's revenue for the
three
months ended in . 20 was IRR0.00 Mil.
Farabi Pharmaceutical does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in . 20.
Farabi Pharmaceutical's Revenue per Share for the
three
months ended in . 20 was IRR0.00.
Farabi Pharmaceutical does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in . 20.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farabi Pharmaceutical Revenue Chart
Farabi Pharmaceutical Annual Data
Trend
Revenue
Farabi Pharmaceutical Quarterly Data
Revenue
XTEH:DFRB1 vs IMNPQ, INNV: Revenue Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Farabi Pharmaceutical's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farabi Pharmaceutical Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Farabi Pharmaceutical's Revenue distribution charts can be found below:
* The bar in red indicates where Farabi Pharmaceutical's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Farabi Pharmaceutical (XTEH:DFRB1) has a Revenue of IRR Mil as of . 20. Revenue is the total amount a company generates as sales through its operations. View historical data on Farabi Pharmaceutical and its competitors.
Is Farabi Pharmaceutical's Revenue too high?
Farabi Pharmaceutical's current Revenue is IRR Mil.
How does Farabi Pharmaceutical's Revenue compare to IMNPQ and INNV?
Farabi Pharmaceutical's Revenue of IRR Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Farabi Pharmaceutical and its competitors. Farabi Pharmaceutical's current Revenue is IRR Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current Revenue of IRR Mil. The current Revenue is IRR Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current Revenue is IRR Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTEH:DFRB1 has been successfully added to your 
